Loading company…
Thioredoxin Systems develops antibiotics for multidrug-resistant infections.
Thioredoxin Systems develops EbsArgent, an antibiotic regimen for complicated urinary tract infections caused by antibiotic-resistant bacteria. It works by disrupting bacterial antioxidant redox systems. Founded in 1994 by Arne Holmgren, the company is based in Stockholm, Sweden. In October 2024, it raised SEK 25 million in Series A funding from Saminvest AB, GU Ventures, Gobia Enterprises and Annexstruktur.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in